NCT02573636View on ClinicalTrials.gov

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

RecruitingOBSERVATIONAL
Enrollment

208

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions
Prostate Cancer
Trial Locations (9)

G7H 5H6

RECRUITING

CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi, Chicoutimi

J4V 2H1

RECRUITING

CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne, Greenfield Park

H7M 3L9

RECRUITING

CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval, Laval

H1T 2M4

RECRUITING

CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montreal

H3T 1E2

RECRUITING

Jewish General Hospital, McGill University, Montreal

H4A 3J1

RECRUITING

MUHC - Cedars Cancer Center, Montreal

G1R 2J6

RECRUITING

CHU - L'Hôtel-Dieu de Québec, Québec

J1H 5N4

NOT_YET_RECRUITING

CIUSSS de l'Estrie - Hôpital Fleurimont, Sherbrooke

G8Z 3R9

RECRUITING

CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières, Trois-Rivières

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

NCT02573636 - The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy | Biotech Hunter | Biotech Hunter